Bridgeworth’s Abiomed Inc ABMD Stock Holding History

Bridgeworth’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-10	Closed	-$4K	–	585
2018 Q2	$4K	Buy	+10	New	+$3.62K	﹤0.01%	532

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Bridgeworth's ABMD Position: Q3 2018 in Review

Bridgeworth sold out of Abiomed Inc (ABMD) in Q3 2018, closing a stake of 10 shares — an estimated $4K sold.

Bridgeworth first reported a position in ABMD in Q2 2018 and held it in 1 quarter. The position peaked at $4K in Q2 2018. 529 funds tracked by Wall St. Rank hold ABMD as of Q3 2018.

Bridgeworth reported no remaining Abiomed Inc position as of Q3 2018 after selling out during the quarter.
Bridgeworth sold 10 Abiomed Inc shares in Q3 2018, an estimated $4K.
Bridgeworth first reported a position in Abiomed Inc in Q2 2018 and held it in 1 quarter.
Bridgeworth's Abiomed Inc position peaked at $4K in Q2 2018.
529 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2018.

Based on Bridgeworth's 13F filing for Q3 2018, filed 13 Nov 2018.